Rami Marouan

Dr. Rami Marouan


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
RMRami Marouan
Rami Marouan
JWJean-Yves Winum
Jean-Yves Winum
Claudiu SupuranClaudiu Supuran
Claudiu Supuran
PMPatricia Melnyk
Patricia Melnyk
SYSaïd Yous
Saïd Yous
Using histamine as lead molecule, a library of (hetero)aryl substituted thiazol-2,4-yl derivatives incorporating pyridine as proton shuttling moiety were obtained and investigated as activators of human carbonic anhydrase (CA, EC 4.2.1.1) isoforms I, II, VII and XIV. Some derivatives displayed good activating and selectivity profiles. This study provides an interesting opportunity to study the thiazole scaffold for the design of CA activators (CAAs), possibly acting on the central nervous system and targeting pathologies involving memory and learning impairments.

5 June 2026 in Molecules
Verified
Journal Article
Open access
PDF file
FDFlorian Descamps
Florian Descamps
RMRami Marouan
Rami Marouan
JGJean-François Goossens
Jean-François Goossens
PMPatricia Melnyk
Patricia Melnyk
LMLiberelle Maxime
Liberelle Maxime
SYSaid Yous
Said Yous
The angiotensin II type 1 (AT1) receptor is a key component of the renin–angiotensin system (RAS) and a validated target for cardiovascular and renal disorders. Developing small molecules with defined AT1 versus AT2 binding profiles remains important for both therapeutic and mechanistic studies. Here, a series of novel imidazole-based compounds was synthesized and evaluated for their binding affinities toward angiotensin II type 1 (AT1) and type 2 (AT2) receptors. Binding studies were conducted by measuring the displacement of radiolabeled [3H]-angiotensin II ([3H]-AII) in PLC-PRF-5 human hepatoma cells for AT1 receptors and calf cerebellum membranes for AT2 receptors. Structure–activity relationship (SAR) analysis revealed that sulfonamide substitution significantly enhanced AT1 receptor affinity, whereas sterically hindered derivatives and ester-containing compounds were less active. Molecular docking studies using the AT1 receptor crystal structure (PDB: 8TH4) rationalized the observed activity trends. The most active compound showed high AT1 affinity (Ki = 5 nM), comparable to losartan, and all compounds displayed preferential binding for AT1 over AT2 receptors.